Cadonilimab and anlotinib for advanced melanoma after first treatment
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs, cadonilimab and anlotinib, for people with melanoma that has gotten worse or spread after their first treatment. It aims to see if this new combination can help when standard options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have been diagnosed with melanoma that has spread or gotten worse after your first treatment
- You can have up to 3 spots in the liver, or brain spots that are stable and not requiring steroids for at least 4 weeks
- You have at least one tumor that can be measured on a scan
- You are feeling well enough to do daily activities (ECOG score 0 or 1)
- You are not breastfeeding, and your organs are working well
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests a combination of two drugs (cadonilimab and interferon) given before surgery to treat advanced melanoma that has spread to nearby lymph nodes or one distant site. The goal is to shrink tumors and improve chances of successful surgery and long-term survival.
This trial tests a new drug called Cardonilmab for people with advanced melanoma or advanced kidney cancer that has not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a combination of three drugs (fruquintinib, cadonilimab, and temozolomide) for people with advanced melanoma that has already been treated with at least one prior therapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.